A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27604324)

Published in Hum Gene Ther Methods on September 07, 2016

Authors

Larissa H Haut1, Amanda L Gill1,2, Raj K Kurupati1, Ang Bian1, Yan Li1, Wynetta Giles-Davis1, Zhiquan Xiang1, Xiang Yang Zhou1, Hildegund C J Ertl1

Author Affiliations

1: 1 The Wistar Institute , Philadelphia, Pennsylvania.
2: 2 Current address: Clinical Molecular Regulation Section/Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland.

Articles cited by this

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99

Adenoviruses as vaccine vectors. Mol Ther (2004) 3.09

Packaging capacity and stability of human adenovirus type 5 vectors. J Virol (1993) 2.76

The innate immune response to adenovirus vectors. Hum Gene Ther (2004) 2.35

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood (2007) 2.21

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis (2006) 1.99

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94

Adenovirus vectors for gene delivery. Curr Opin Biotechnol (1999) 1.89

Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol (2003) 1.75

Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol (2010) 1.58

Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol (2003) 1.58

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis (2015) 1.57

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol (2005) 1.52

HIV-1 vaccines. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science (2015) 1.43

Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem (2000) 1.42

Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol (2005) 1.29

Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol (1998) 1.25

Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine (2009) 1.24

Immune evasion by adenovirus E3 proteins: exploitation of intracellular trafficking pathways. Curr Top Microbiol Immunol (2004) 1.18

Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses. Virus Genes (2000) 1.15

An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc (2010) 1.07

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol (2015) 0.98

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother (2006) 0.95

The humoral response to HIV-1: new insights, renewed focus. J Infect Dis (2010) 0.91

An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine (2009) 0.88

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One (2014) 0.86

Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA regulation. Mol Ther Methods Clin Dev (2015) 0.86

Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents. Infect Immun (2013) 0.86

Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther (2014) 0.85

Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit. J Virol (2007) 0.84

Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. J Immunol (2014) 0.84

Phage-displayed mimotopes recognizing a biologically active anti-HIV-1 gp120 murine monoclonal antibody. J Acquir Immune Defic Syndr (2002) 0.83

Immunological and virological analyses of rhesus macaques immunized with chimpanzee adenoviruses expressing the simian immunodeficiency virus Gag/Tat fusion protein and challenged intrarectally with repeated low doses of SIVmac. J Virol (2013) 0.82

Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology (2014) 0.80

Genetic signatures of HIV-1 envelope-mediated bystander apoptosis. J Biol Chem (2013) 0.80

Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization. DNA Cell Biol (2000) 0.80

Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection. Hum Gene Ther (2014) 0.80

The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion. J Immunol (2014) 0.80

Progress on adenovirus-vectored universal influenza vaccines. Hum Vaccin Immunother (2015) 0.80

Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques. J Virol (2014) 0.78

Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment. PLoS One (2015) 0.76

Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine. Sci Rep (2015) 0.76

Immunogenicity and protective efficacy of a recombinant adenoviral based vaccine expressing heat-stable enterotoxin (STa) and K99 adhesion antigen of enterotoxigenic Escherichia coli in mice. Mol Immunol (2015) 0.76